{"title":"Use of finasteride plus doxazosin combination therapy for treatment of LUTS related to benign prostatic hyperplasia","authors":"J. Dall'era, L. Byrne, A. Barqawi","doi":"10.2217/1745509X.3.4.437","DOIUrl":null,"url":null,"abstract":"The incidence of benign prostatic hyperplasia and resulting lower urinary tract symptoms increases with age. This constellation of symptoms, including urinary frequency, urinary urgency and nocturia, has been the source of much morbidity in the aging male, and the focus of many pharmaceutical developments. Understanding the progressive disease process and treatment guidelines for lower urinary tract symptoms resulting from benign prostatic hyperplasia is crucial for urologists and primary-care physicians managing the aging population. Multiple large, randomized, controlled studies have been performed to evaluate the benefits of two of the currently used medications in the treatment of benign prostatic hyperplasia: finasteride and doxazosin. The advantages of each medication used alone or in combination have been well described in these trials. The scope of this review is to present a concise summary of these important trials with special emphasis on the long-term safety profile of these medications. Furth...","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"437-443"},"PeriodicalIF":0.0000,"publicationDate":"2007-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.4.437","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/1745509X.3.4.437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The incidence of benign prostatic hyperplasia and resulting lower urinary tract symptoms increases with age. This constellation of symptoms, including urinary frequency, urinary urgency and nocturia, has been the source of much morbidity in the aging male, and the focus of many pharmaceutical developments. Understanding the progressive disease process and treatment guidelines for lower urinary tract symptoms resulting from benign prostatic hyperplasia is crucial for urologists and primary-care physicians managing the aging population. Multiple large, randomized, controlled studies have been performed to evaluate the benefits of two of the currently used medications in the treatment of benign prostatic hyperplasia: finasteride and doxazosin. The advantages of each medication used alone or in combination have been well described in these trials. The scope of this review is to present a concise summary of these important trials with special emphasis on the long-term safety profile of these medications. Furth...